1. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report — 95. 2020. [Electronic resource]. URL:https://www.who.int/docs/default-source/coronaviruse/situationreports/20200424-sitrep-95-covid-19.pdf?sfvrsn=e8065831_4. (date of the application: 07 Nov 2020)
2. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)» Министерства здравоохранения Российской Федерации (Версия 8.1 (01.10.2020)) [Электронный ресурс]. URL: https://www.rosminzdrav.ru/ministry/med_covid19. (дата обращения: 07 ноября 2020).
3. Guan W.J., Ni Z.Y., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382:1708-1720. doi:10.1056/NEJMoa2002032.
4. Potekaev N.N., Zhukova O.V., Protsenko D.N. et al. Clinical characteristics of dermatologic manifestations of COVID-19 infection: case series of 15 patients, review of literature, and proposed etiological classification. Int J Dermatol. 2020; 59(8):1000-1009. doi:10.1111/ijd.15030.
5. Ortega-Quijano D., Jimenez-Cauhe J., Selda-Enriquez G. et al. Algorithm for the classification of COVID-19 rashes. J Am Acad Dermatol. 2020; 83(2):e103-e104. doi:10.1016/j.jaad.2020.05.034.
6. De Giorgi V., Recalcati S., Jia Z. et al. Cutaneous manifestations related to corona virus disease 2019 (COVID-19): A prospective study from China and Italy. J Am Acad Dermatol. 2020; 83(2):674-675. doi: 10.1016/j.jaad.2020.05.073.
7. Su C.J., Lee C.H. Viral exanthem in COVID-19, a clinical enigma with biological significance. J EurAcadDermatolVenereol. 2020; 34(6):e251-e252. doi: 10.1111/jdv.16469.
8. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020; 34(5): e212-e213. doi: 10.1111/jdv.16387.
9. Marzano A.V., Genovese G., Fabbrocini G. et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol. 2020; 83(1):280-285. doi: 10.1016/j.jaad.2020.04.044.
10. Joob B., Wiwanitkit V. Hemorrhagic problem among the patients with COVID-19: clinical summary of 41 Thai infected patients. Clin Appl Thromb Hemost. 2020; 26: 1076029620918308. doi:10.1177/1076029620918308.
11. Henry D., Ackerman M., Sancelme E. et al. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol. 2020; 34(6):e244-e245. doi: 10.1111/jdv.16472.
12. Zhang Y., Cao W., Xiao M. et al. Clinical and coagulation characteristics in 7 patients with critical COVID-2019 pneumonia and ac ro-ischemia. ZhonghuaXue YeXueZaZhi. 2020; 41(4): 302-307. doi: 10.3760/cma.j.issn.0253-2727.2020.008.
13. Kanitakis J., Lesort C., Danset M. et al. Childblain-like acral lesions during the C OVID-19 pandemic (“COVID toes”): Histologic, immunofluorescence and immunohistochemical study of 17 cases. J Am Acad Dermatol. 2020; 83(3):870-875. doi: 10.1016/j.jaad.2020.05.145.
14. Jia J.L., Kamceva M., Rao S.A. et al. Cutaneous manifestations of COVID-19: A preliminary review.J Am Acad Dermatol. 2020; 83(2):687-690. doi:10.1016/j.jaad.2020.05.059.
15. Vesely M.D., Perkins S.H. Caution in the time of rashes and COVID-19. J Am AcadDermatol. 2020; 83(4): e321-e322. doi: 10.1016/j.jaad.2020.07.026.
16. Roncati L., Ligabue G., Fabbiani L. et al. Type 3 hypersensitivity in COVID-19 vasculitis.ClinImmunol . 2020; 217: 108487. doi:10.1016/j.clim.2020.108487.
17. Galvan Casas C., Catala A., Carretero Hernandez G. et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br. J. Dermatol. 2020; 183(1):71-77. doi: 10.1111/bjd.19163.
18. Mazzotta F, Troccoli T. Acute acro-ischemia in the child at the time of COVID-19. Eur. J. Ped. Dermatol.2020; 30(2): 71–74.doi: 10.26326/2281-9649.30.2.2102.
19. Kolivras A., Dehavay F., Delplace D., et al. Coronavirus (COVID-19) infection-induced chilblains: a case report with histopathological findings. JAAD Case Reports. 2020; 6(6): 489-492. doi: 10.1016/j.jdcr.2020.04.011.
20. Dursun R, Temiz SA. The clinics of HHV-6 infection in COVID-19 pandemic: Pityriasisrosea and Kawasaki. Dermatol Ther. 2020;e13730.doi:10.1111/dth.13730.
21. Kang J.H. Febrile illness with skin rashes. Infect Chemother. 2015; 47(3): 155-166.doi:10.3947/ic.2015.47.3.155.
22. Hedou M., Carsuzaa F., Chary E. et al. Comment on “Cutaneous manifestations in COVID-19: a first perspective” by Recalcati S. J Eur Acad Dermatol Venereol. 2020; 34(7): e299-e300. doi: 10.1111/jdv.16519.
23. Jones V.G., Mills M., Suarez D. et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr. 2020; 10(5): 537-540. doi: 10.1542/hpeds.2020-0123.
24. Лучшева В.И., Жарова С.Н., Никифорова В.В. Атлас инфекционных болезней. Издательская группа «ГЭОТАР-Медиа». 2014; 224 с.
25. Tammaro A., Adebanjo G.A.R., Parisella F.R. et al. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. J Eur Acad Dermatol Venereol. 2020; 34(7): e306-e307. doi: 10.1111/jdv.16530.
26. Van Damme C., Berlingin E., Saussez S. et al. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. J Eur Acad Dermatol Venereol. 2020; 34(7): e300-e301. doi: 10.1111/jdv.16523.
27. Joob B., Wiwanitkit V. COVID-19 in medical personnel: observation from Thailand. J Hosp Infect. 2020; 104(4): 453. doi: 10.1016/j.jhin.2020.02.016.
28. Elston D.M. Occupational skin disease among health care workers during the coronavirus (COVID-19) epidemic. J Am Acad Dermatol. 2020; 82(5): 1085-1086. doi: 10.1016/j.jaad.2020.03.012.
29. Schwartz R.A., Reynoso-Vasquez V., Kapila R. Chloronychia: the Goldman-fox syndrome: implications for patients and health care workers. Indian J Dermatol. 2020; 65(1): 1-4. doi: 10.4103/ijd.IJD_277_19.
30. Soria A., Barbaud A., Assier H. et al. Cutaneous adverse drug reactions with antimalarials and allergological skin tests. Dermatology.2015; 231(4): 353-359. doi: 10.1159/000438787.
31. Wang C., Rademaker M., Baker C. et al. COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: an Australia/New Zealand consensus statement. Australas J Dermatol. 2020; 61(3): 210-216. doi: 10.1111/ajd.13313.
32. Wollenberg A., Flohr C., Simon D. et al. European task force on atopic dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis. J EurAcad Dermatol Venereol. 2020; 34(6): e241-e242. doi: 10.1111/jdv.16411.
33. Schwartz R.A., Kapila R. Cutaneous manifestations of a 21st century worldwide fungal epidemic possibly complicating the COVID-19 pandemic to jointly menace mankind. DermatolTher. 2020; 33(4): e13481. doi: 10.1111/dth.13481.
34. Van Doremalen N., Bushmaker T., Morris D.H. et al. Aerosol and surfacestability of SARS-CoV-2 as compared with SARSCoV-1. N Engl J Med. 2020; 382(16): 1564-1567. doi: 10.1056/NEJMc2004973.
35. Российское общество дерматовенерологов и косметологов. Клинические рекомендации МЗ РФ «Токсидермия». 2016; 26с.
36. Таирова Р.Т., Гайдина Т.А., Дворников А.С. и др. Сложности дифференциальной диагностики кожных проявлений при коронавирусной инфекции. Вестник РГМУ. 2020; 5: 72-78. doi: 10.24075/vrgmu.2020.062.
37. Verduyn M., Allou N., Gazaille V. et al. Co-infection of dengue and COVID-19: A case report. PLoS Negl Trop Dis. 2020; 14(8): e0008476. doi: 10.1371/journal.pntd.0008476.
38. Sun J., Aghemo A., Forner A. et al. COVID-19 and liver disease. Liver Int. 2020; 40(6): 1278–1281. doi: 10.1111/liv.14470.
39. Lucas C., Wong P., Klein J. et al. Longitudinal analyses reveal immunological misfiring in se vere COVID-19. Nature. 2020; 584(7821): 463-469. doi: 10.1038/s41586-020-2588-y.
40. Gu J., Han, B., Wang J. COVID-19: gastrointestinal manifestations and poten tial fecal–oral transmission. Gastroenterology. 2020; 158(6): 1518-1519. doi: 10.1053/j.gastro.2020.02.054.
41. Ивашкин В.Т., Шептулин А.А., Зольникова О.Ю. др. Новая коронавирусная инфекция (COVID-19) и система органов пищеварения. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020; 30(3): 7-13. doi: 10.22416/1382-4376-2020-30-3-7.